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NXY-059 for the Treatment of Acute Stroke
Pooled Analysis of the SAINT I and II Trials
Hans-Christoph Diener, MD; Kennedy R. Lees, MD; Patrick Lyden, MD; Jim Grotta, MD;
Antoni Davalos, MD; Stephen M. Davis, MD, PhD; Ashfaq Shuaib, MD; Tim Ashwood, PhD;
Warren Wasiewski, MD; Vivian Alderfer, PhD; Hans-Goran Hårdemark, MD;
Larry Rodichok, MD; for the SAINT I and II Investigators
Background and Purpose—In animal models of acute ischemic stroke (AIS), the free radical–trapping agent NXY-059
showed promise as a neuroprotectant. SAINT I and II were randomized, placebo-controlled, double-blind trials to
investigate the efficacy of NXY-059 in patients with AIS.
Methods—Patients with AIS received an infusion of intravenous NXY-059 or placebo within 6 hours from the onset of
stroke symptoms. A pooled individual patient analysis was prespecified to assess the overall efficacy and to examine
subgroups. The primary end point was the distribution of disability scores measured on the modified Rankin scale (mRS)
at 90 days. Neurologic and activities of daily living scores were investigated as secondary end points. We also evaluated
whether treatment with NXY-059 would reduce alteplase-related intracranial hemorrhages. Finally, we evaluated
possible predictors of good or poor outcome.
Results—An intent-to-treat efficacy analysis was based on 5028 patients. Baseline parameters and prognostic factors were
well balanced between treatment groups. The distribution of scores on the mRS was not different in the group treated
with NXY-059 (n2438) compared with the placebo group (n2456): odds ratio for limiting disability1.02; 95% CI,
0.92 to 1.13 (P0.682, Cochran-Mantel-Haenszel test). Comparisons at each level of the mRS confirmed an absence
of benefit. There was no evidence of efficacy in prespecified subgroups or from the secondary outcome analyses.
Mortality was equal in the 2 groups (16.7% vs 16.5%), and adverse event rates were similar. Among patients treated
with alteplase, there was no decrease in rates of symptomatic or asymptomatic hemorrhage associated with NXY-059
treatment versus placebo. Subgroup analyses identified National Institutes of Health Stroke Scale score, age, markers
of inflammation, blood glucose, and right-sided infarct as predictors of poor outcome.
Conclusions—NXY-059 is ineffective for treatment of AIS within 6 hours of symptom onset. This is also true for
subgroups and the prevention of alteplase-associated hemorrhage. (Stroke. 2008;39:1751-1758.)
Key Words: ischemic stroke  neuroprotective therapy  pooled analysis  thrombolysis  predictors of outcome
Thrombolysis with alteplase (recombinant tissue-type plas-minogen activator) is the only approved drug treatment for
acute stroke in a 3-hour time window.1 There is an urgent need
for new therapies that are safer and can be offered to a higher
percentage of patients over a longer time period after the event.
Cerebral tissue can be protected in animal models by a variety of
medications that attenuate neuronal injury after ischemia,2 but no
neuroprotective drug has been approved for use in humans.
NXY-059, a potent free radical–trapping agent, has been exten-
sively tested in small- and large-animal models of focal ischemic
stroke and has been shown to improve functional recovery and
reduce the size of the cerebral infarction.3 A first study showed
that NXY-059 was significantly better than placebo in improv-
ing outcome when tested in patients with ischemic stroke treated
within 6 hours from the onset of symptoms.4,5 Suggesting a
biologic signal, post hoc analysis of the data also revealed that
treatment with NXY-059 significantly reduced the incidence of
intracranial hemorrhages among patients in whom alteplase was
also used.4 The second phase III study with a larger sample,
however, was neutral for the primary and all secondary out-
comes.6 Pooled individual patient analysis of the 2 trials was
prespecified to examine efficacy and especially to consider sub-
groups. This article reports the pooled analysis of the 2 studies and
investigated possible baseline predictors of poor or good outcome.
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Patients and Methods
Study Design
SAINT I and II were 2 randomized, double blind, placebo-controlled
studies that enrolled patients from May 2003 through June 2006. The
trials included 498 centers from 38 countries, with local or national
institutional ethics review board approval as appropriate. Patients were
randomized only if informed consent was obtained from the patient or,
if the patient was unable to consent, from an acceptable surrogate.
The design and conduct of the 2 SAINT studies were developed by
a steering committee comprising stroke experts from Europe, North
America, and Australia. The steering committee had complete access
to all data and was responsible for writing the manuscript. An
independent data safety monitoring committee was responsible for
safety reviews and futility analysis. The sponsor, AstraZeneca, was
responsible for operational aspects of the trial, including collecting
and storing the data and performing the analysis according to the
approved statistical analysis plan.
Patients
Patients were eligible for enrollment if they were 18 years or older
and had a clinical diagnosis of acute ischemic stroke within 6 hours
of symptom onset. They had to score at least 6 on the National
Institutes of Health Stroke Scale (NIHSS)7 with at least 2 points for
limb weakness. All patients received appropriate routine stroke care
as per local treatment practices, including alteplase for eligible
patients presenting 3 hours from onset; patients receiving alteplase
had to commence the study drug within 30 minutes of completion of
the alteplase infusion.
Study Intervention
Patients were randomly assigned by a computer-generated coding
system to receive an intravenous infusion of either NXY-059 or
placebo. Sites were required to maintain an average time to start of
the study drug infusion of 4 hours. Randomization was stratified
according to country, NIHSS score at baseline, side of infarction, and
intention to treat with alteplase. AstraZeneca supplied the study drug
as a concentrate to be diluted to 15 mg/mL in 500 mL of 0.9% saline
solution. Matching placebo was handled similarly. The initial infu-
sion rate (bolus) was 2270 mg/h and was reduced after 1 hour to 480
to 960 mg (32 to 64 mL) per hour for a further 71 hours, with the aim
of maintaining a target serum concentration of 260 mol unbound
study drug per liter. The infusion rate was guided by the estimated
rate of creatinine clearance based on the serum creatinine concen-
tration8 and was adjusted to 32 mL/h for a clearance of 30 to 50
mL/min, 44 mL/h for a clearance of 51 to 80 mL/h, and 64 mL/h for
values 80 mL/h. Patients with a creatinine clearance of 30 mL/h
were withdrawn from treatment.
Clinical Assessment
Patients were assessed at the time of enrollment; 24 and 72 hours after
start of the study drug; and on days 7, 30, and 90. Initial assessments
included physical examination, neuroimaging, and a NIHSS assessment
to determine stroke severity. Examiners were trained and certified in the
use of the NIHSS examination (scores range from 0 to 42, with a higher
score indicating greater stroke severity).9
Assessments after completion of the study drug infusion were
primarily functional or neurologic, including the modified Rankin
scale (mRS)10 (days 7, 30, and 90), the NIHSS (days 7 and 90), and
the Barthel Index11 (days 7, 30, and 90). Additional outcome
measures included the Stroke Impact Scale and the Euro-QoL 5D.
The mRS is a global disability scale with a range from 0, indicating
no residual symptoms, to 5, for patients who are bedridden and
require constant care. In this study, patients who died were assigned
a score of 5 on the mRS. Investigators were trained, tested, and
certified in use of the mRS by using a DVD method developed
specifically in preparation for this trial.12 The NIHSS quantifies the
level of neurologic deficit, with higher scores at 90 days predictive
of dependence.13 The Barthel Index is an activities-of-daily-living
scale ranging from 0 to 100, with 100 indicating independence and
0 indicating complete dependence.
5028 Patients underwent randomization
4946 (98.4%) started infusion 
82 did not start treatment 
2487 assigned to placebo 
2459 assigned to NXY-059 
2478 received only 
placebo and were 
included in the
safety population
Crossovers
26 patients assigned to placebo 
and 17 assigned to NXY-059 
crossed over to the alternative 
treatment group 
2468 received some 
NXY-059 and were 
included in the safety 
population 
51 (1.0%) Withdrew or were lost to follow-
up before first assessment 
1 SAINT II patient not included in efficacy 
analysis due to incomplete stratification 
2456 included in the 
efficacy analysis 
2438 included in the 
efficacy analysis 
Figure 1. Allocation of patients for this
study (combined SAINT II and II).
Table 1. Demographic Characteristics of Patients Included in
the Safety Analysis (SAINT I and II)
Parameter
NXY-059
n2468
Placebo
n2478
Sex
Male 1373 (55.6%) 1342 (54.2%)
Female 1095 (44.4%) 1136 (45.8%)
Age, y
Median 71.0 71.0
Race
White 2120 (85.9%) 2141 (86.4%)
Black 93 (3.8%) 75 (3.0%)
Oriental 213 (8.6%) 210 (8.5%)
Other 42 (1.7%) 52 (2.1%)
BMI, kg/m2
Median 26.4 26.3
Weight, kg
Median 75.0 75.0
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Safety Assessments
Vital signs were recorded at enrollment and at specified times
throughout the infusion and follow-up periods. Routine laboratory
data and ECGs were performed at the time of enrollment, at 24 and
72 hours, and on day 7 and were analyzed centrally (ECGs at day 7
were performed only if abnormal at 72 hours). To assess any effect
of NXY-059 on hemorrhagic transformation after alteplase admin-
istration, brain imaging was repeated after 72 hours in patients who
were receiving concomitant treatment with alteplase. Symptomatic
hemorrhagic transformation was defined as an increase in the NIHSS
score of at least 4 points within 36 hours, plus evidence of any blood
on neuroimaging after treatment with alteplase. Patients meeting
criteria for progressive stroke (NIHSS increase of 4 points within
72 hours) or new stroke in the first week were also reimaged.
Follow-up scans were read centrally, and readers were blinded to
treatment allocation.
Statistical Analysis
The pooled analyses were prespecified and followed the intention-
to-treat principle, except that only those patients who commenced
any investigational infusion were considered. For efficacy purposes,
patients were analyzed according to the intended treatment group.
The primary outcome measure was the mRS score at 90 days or on
last rating, analyzed across the whole distribution of scores by the
Cochran-Mantel-Haenszel test with a modified ridit score, with
adjustment for baseline variables of NIHSS score, side of infarct, and
alteplase use,14 the preferred scoring system that produces van
Elteren’s extension of the Wilcoxon rank-sum test for stratified
analyses. Dichotomized and trichotomized mRS results were also
analyzed.
The sample size estimations for the 2 SAINT trials were reported
previously.4,6 Deaths were included within the worst outcome
category (mRS score5). Neurologic function was assessed by the
total NIHSS score, the first secondary end point, at 90 days or on last
rating, and was analyzed with the Cochran-Mantel-Haenszel test
with a modified ridit score and adjusted for baseline variables of
NIHSS score, side of infarct, and alteplase use.
Analysis of efficacy outcomes was ordered hierarchically. This
avoided the need for further adjustment for multiplicity because
formal statistical testing was performed only when the preceding end
point was significant. The primary end point mRS score was the first
Table 2. Baseline Characteristics of Patients Included in the
Safety Analysis (SAINT I and II)
Parameter
NXY-059
n2468
Placebo
n2478
History of diabetes mellitus 547 (22.2%) 588 (23.7%)
History of hypertension 1834 (74.3%) 1831 (73.9%)
History of and/or atrial fibrillation
at admission
678 (27.5%) 768 (31.0%)
History of congestive heart
failure at admission
243 (9.8%) 224 (9.0%)
History of ischemic heart disease 806 (32.7%) 820 (33.1%)
History of myocardial infarction 321 (13.0%) 320 (12.9%)
History of arrhythmia 264 (10.7%) 244 (9.8%)
History of previous stroke 482 (19.5%) 497 (20.1%)
History of ischemic stroke 482 (19.5%) 497 (20.1%)
History of transient ischemic
attack
288 (5.7%) 133 (5.4%)
Subclassification of stroke*
Cardioembolic 1098 (44.7%) 1153 (46.7%)
Noncardioembolic 1357 (55.3%) 1316 (53.3%)
History of smoking†
Nonsmoker 1348 (54.8%) 1419 (57.3%)
Ex-smoker 512 (20.8%) 547 (22.1%)
Occasional smoker 75 (3.0%) 54 (2.2%)
Habitual smoker 526 (21.4%) 455 (18.4%)
Prior use of antiplatelet agent 830 (33.6%) 839 (33.9%)
Prior use of anticoagulants 247 (10.0%) 260 (10.5%)
Plasma glucose at
admission, mmol/L‡
0–2.5 2 (0.1%) 1 (0.0%)
2.5 to 3.9 14 (0.7%) 17 (0.8%)
3.9 to 6.1 716 (33.8%) 734 (33.9%)
6.1 to 8.0 823 (38.8%) 805 (37.2%)
8.0 to 10.0 282 (13.3%) 302 (14.0%)
10.0 283 (13.3%) 304 (14.1%)
Total NIHSS score at baseline¶
Mean 12.9 12.8
SD 5.5 5.5
Median 12.0 12.0
6–9 877 (35.5%) 892 (36.0%)
10–14 697 (28.2%) 711 (28.7%)
15–19 539 (21.8%) 523 (21.1%)
20 355 (14.4%) 352 (14.2%)
Side of infarct
Right 1318 (53.4%) 1308 (52.8%)
Left 1150 (46.6%) 1169 (47.2%)
Alteplase treatment
No 1518 (61.5%) 1513 (61.1%)
Yes 950 (38.5%) 965 (38.9%)
(Continued )
Table 2. Continued
Parameter
NXY-059
n2468
Placebo
n2478
Time from onset of stroke to
start of infusion, h:min
Mean 03:46 03:48
SD 00:55 00:57
Median 03:45 03:45
Time from onset of stroke to
start of infusion
0 to 2 hours 50 (2.0%) 55 (2.2%)
2 to 3 hours 482 (19.5%) 492 (19.9%)
3 to 4 hours 1137 (46.1%) 1083 (43.7%)
4 to 5 hours 534 (21.6%) 574 (23.2%)
5 to 6 hours 265 (10.7%) 268 (10.8%)
6 hours 0 (0.0%) 6 (0.2%)
*Based on 2455 patients treated with NXY-059 and 2469 treated with
placebo.
†Based on 2461 (NXY-059) and 2475 (placebo) patients.
‡Based on 2120 (NXY-059) and 2163 (placebo) patients.
¶Scores on the NIHSS range from 0, indicating normal functioning, to 42,
indicating most severe impairment.
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in the hierarchy of outcomes, and a positive result would have been
declared if this was significant, irrespective of end points lower in
the hierarchy.
Safety end points included mortality, serious and nonserious adverse
events, laboratory parameters, vital signs, and neuroimaging data. The
incidence of intracranial hemorrhage in patients who were treated
concomitantly with alteplase was prospectively analyzed by the 2 test.
Descriptive statistics (number and frequency) were summarized for all
intracranial hemorrhages for each treatment group.
Prospectively identified prognostic/risk factors were entered into a
logistic-regression model with mRS score at day 90 as the response
variable. With the stepwise selection method within the PROC
LOGISTIC computational environment in SAS, predictors of the
response variable were retained in the model if the 0.05 significance
level criterion was met. The selected model was refitted with the
addition of a main effects interaction, and goodness of fit was
assessed with the deviance criterion calculated from the observed
and expected frequencies of the response variable. Odds ratios (ORs)
and 95% CIs were obtained from exponents of the parameter
estimates. Percent change was calculated from 100(OR1) for
interpretation of the ORs.
Results
Baseline Characteristics
Of the 5028 patients randomized, 4946 patients received
study treatment, with 2468 patients treated with NXY-059
and 2478 treated with placebo (Figure 1). The numbers of
crossovers and of patients who withdrew from the study are
shown in Figure 1. Demographic and baseline characteristics
are shown in Tables 1 and 2. The mean time from onset of
symptoms to start of study drug infusion was 3 hours, 47
minutes. One thousand nine hundred fifteen patients (38.7%)
received treatment with alteplase. Of the 1876 NXY-059–
treated patients with plasma concentration data, 1803 (96.1%)
reached a plasma concentration of 150 mol/L or greater,
well above the levels that were shown to be neuroprotective
in animal models of stroke.
Clinical Outcomes
The distribution of scores on the mRS at 90 days was similar
in both groups (P0.682, n4894, Cochran-Mantel-
Haenszel test; OR for favorable outcome1.02; 95% CI, 0.92
to 1.13; Figure 2). Analysis of the per-protocol group,
patients who completed at least 75% of the infusion and who
complied fully with the protocol, also did not show any
significant difference between the 2 groups (Cochran-Mantel-
Haenszel test, P0.733; OR1.02; 95 CI, 0.91 to 1.13).
There were no significant effects noted at 7 and 30 days
between the NXY-059– and placebo-treated groups.
There was no effect of NXY-059 on any of the prespecified
secondary end points. The total NIHSS score at last rating in
the NXY-059 group was not significantly different from that
in the placebo-treated group (Cochran-Mantel-Haenszel test,
P0.726; Mann-Whitney rank statistic, 0.50; 95% CI, 0.48 to
0.52). In addition, there was no difference in the percentage
of patients who made a complete recovery (NIHSS score of 0
vs 1 to 42: 18.2% in the NXY-059– vs 16.9% in the
placebo-treated group). There was no difference in the pro-
portion of patients attaining a Barthel Index score of 95 or
more between the NXY-059–treated and the placebo treated
group (43.3% NXY-059 vs 40.8% placebo). Finally, there
was no difference in mortality (Figure 3).
In our prespecified analysis of patients treated with alte-
plase, there were no significant differences in the percentage
of patients who developed symptomatic (4.1% vs 5.6%,
Figure 3. Survival curves. The number of deaths in
the NXY-059 group (267, or 16.6%) was virtually
identical to that among placebo-treated patients
(266, or 16.4%).
Figure 2. Primary outcome at 90 days,
according to scores on the mRS, in the
intention-to-treat analysis.
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NXY-059 vs placebo, P0.129), asymptomatic (16.6% vs
17.3%, NXY-059 vs placebo, P0.694), or overall combined
(20.7% vs 22.9%, NXY-059 vs placebo, P0.252; Figure 4)
cerebral hemorrhages. There were no interactions between the
treatment effect of NXY-059 and the time from stroke onset to
treatment (4 hours vs 4 hours), the severity of stroke
(based on NIHSS score), or the use of alteplase (Figure 5).
Subgroup Analyses
Logistic-regression analysis identified 6 baseline characteris-
tics as predictors of outcome. These are shown in Table 3. As
expected, an increase in the severity of stroke and age were
the most important factors for poor outcome. Left-sided
infarcts had a better prognosis. Increased neutrophil count as
a sign of ongoing inflammation predicted poor outcome.
Higher glucose values also predicted poor outcome.
Intake of antiplatelet medication has been associated with
a better outcome in some studies or case-control series.
Therefore, we compared stroke severity at baseline, measured
by the NIHSS, between patients on (n1669) and off
(n3266) antiplatelet treatment at randomization. The anal-
ysis took possible confounders into consideration. There was
no difference between the patient categories (OR0.80; 95%
CI, 1.68 to 0.08; P0.08).
We analyzed whether very high or very low blood pressure
(BP) had an influence on outcome. Low BP was defined as
120/80 mm Hg or 160/100 mm Hg, and the outcome con-
sidered was the mRS score. There were 689 patients (15.1%)
whose BP fell outside the normal range and 3880 (84.9%) whose
BPs were within the normal range. Five hundred sixty (12.4%)
had an increase in systolic BP of 20 mm Hg in the first 48
hours. The marginally better outcome with a normal-range BP
(OR1.16; 95% CI, 0.97 to 1.38) was not significant (P0.095).
We considered whether during the first 48 hours increases
in BP of 20 mm Hg or decreases of 30 mm Hg had an
influence on outcome. The estimated effect on the final mRS
score, adjusted for the baseline predictors, indicated a numer-
ically better outcome in patients not experiencing a BP
increase, but the effect was not statistically significant
(OR1.17; 95% CI, 096 to 1.41; P0.12).
Finally, we dichotomized patients according to admission
blood glucose, with 160 mg/dL (8.8 mmol/L) as the cutpoint.
The 846 patients who had blood glucose levels above the
cutpoint had a poorer prognosis than did the 3397 patients who
had normal blood glucose values (OR1.46; 95% CI, 1.26 to 1.71).
Safety Analysis
There was no difference in mortality for patients treated with
NXY-059 (413/2468 (16.7%) compared with placebo (408/
2478, or 16.5%) as shown in Figure 4. The most common
causes of death were neurologic damage from the initial
stroke (NXY-059 n123 [25.4%] vs placebo n153
[32.5%]) and bronchopneumonia (NXY-059 n68 [14.0%]
vs placebo n61 [13.0%]). Adverse events were reported in
81.8% of patients in the NXY-059–treated group compared
with 82.6% of patients in the placebo-treated group. Serious
adverse events were reported in 37.8% of NXY-059–treated
and in 39.1% of placebo-treated patients. The proportion of
patients who discontinued medication due to adverse events
was 4.7% for NXY-059 and 6.6% for placebo. The only
adverse event seen more frequently in the NXY-059–treated
group was hypokalemia (10.1% vs 7.5%, NXY-059 vs
placebo), but this was not associated with cardiac or other
complications and resolved by 7 days.
Discussion
The pooled analysis of the SAINT trials presented here
confirms neutral results, not only in the overall population but
now also in important prespecified subgroups, such as those
treated early after stroke or those who were offered alteplase.
The trial program for NXY-059 in ischemic stroke was
extensive and rigorous. Despite adequate power with a
considerable sample size for an acute stroke trial and use of
an accepted primary outcome, the mRS score, we failed to
confirm the efficacy of NXY-059.
SAINT I showed promising results, with a reduction in
global disability,4,5 and showed benefit in some of the
secondary end points. SAINT II with more patients was
neutral for the primary and key secondary outcomes. In
SAINT I, patients treated with alteplase and NXY-059 had
Figure 4. Occurrence of symptomatic (SICH) and
asymptomatic intracranial hemorrhages in patients
treated with alteplase, depending on assignment
to NXY-059 or placebo.
Diener et al Results of the SAINT Trials 1755
 at GLASGOW UNIV LIB on January 19, 2012http://stroke.ahajournals.org/Downloaded from 
fewer cerebral hemorrhages than did those given placebo,4 an
effect we failed to confirm in SAINT II6 or in this pooled
analysis. NXY-059 had a good safety profile with no differ-
ence in mortality and, with the exception of hypokalemia, no
other relevant adverse events were observed.
Large clinical trials offer an opportunity to explore sub-
groups of patients or comorbidities influencing outcome. This
is important for the design of future clinical trials.15,16 We
prospectively identified predictors of poor outcome, finding
that age and severity of stroke measured by the NIHSS were
the most important predictors,17 followed by neutrophil count
and blood glucose value. Systemic and local inflammation18
is a risk factor for stroke and a predictor of poor outcome.19
Elevated glucose level and diabetes mellitus are well-known
predictors of poor outcome.20,21 In contrast to earlier stud-
ies,22,21 we were not able to show a protective effect of
antiplatelet therapy at the time of the qualifying stroke. We
found a trend for poor outcome with both very low and increased
Figure 5. Forest plot of baseline variables, with
possible influence on outcome (mRS score), time
interval from stroke onset to onset of treatment,
use or nonuse of recombinant tissue-type plasmin-
ogen activator, and NIHSS score at baseline.
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BP, which was not significant. Other trials have shown a clear
influence of BP and BP changes on outcome.23–25
The NXY-059 trial program shows how difficult it is to
perform trials with neuroprotective substances in acute ische-
mic stroke. The partly positive result of the first trial, SAINT
I, could not be confirmed by the larger SAINT II trial,
suggesting that the initially favorable result in SAINT I was
likely a chance finding. Other than the larger sample size, the
most obvious difference in SAINT II was the higher fre-
quency of alteplase use (44% vs 28.7%).6 The higher rate of
alteplase use in SAINT I is unlikely to explain the different
results in the 2 SAINT trials because there was no interaction
between alteplase use and NXY-059 effect in either trial. The
most probable explanation is an imbalance in baseline factors
in SAINT I that favored the active treatment group. Analyz-
ing the known predictors of outcome, we could not identify
which baseline variables might have influenced the outcome,
and the possibility that the different recombinant tissue-type
plasminogen activator use rates explains the difference in the
2 trials cannot be conclusively excluded.
The reduced rate of hemorrhagic transformation associated
with NXY-059 after thrombolysis in SAINT I indicated a
neuroprotective action of NXY-059.4 This observation also
could not be replicated in SAINT II. Experimental data
support the notion that free radicals play an important role in
blood–brain barrier damage after stroke by activating matrix
metalloproteinases and other proteases.26,27
What are the lessons to be learned? Despite following
STAIR criteria28–31 in the development of NXY-059 and
using up-to-date study design and statistical methods, the
pooled analysis showed no benefit of the active drug. Perhaps
data gained from rats and small primates cannot be transferred to
the treatment of human stroke. It is not enough simply to move
on: rigorous reexamination of the experimental models and data
should now be undertaken to explore the role of preclinical data
for future candidate treatments. For the time being, the STAIR
criteria do not offer a validated means of predicting the results of
a neuroprotective trial. Second, we have seen that even a trial of
1700 patients can produce misleading results: we need to
consider whether our attention to outcome assessment, though
strictly controlled, was sufficiently rigorous. For example, per-
haps video recording of outcomes with central adjudication is
now required to limit interobserver variation, drift, and bias. We
need to explore our management of patients beyond the crucial
first few days of acute care to discover whether wide variations
in rehabilitation practices conceals useful treatment benefits, not
only because we may be abandoning useful approaches unnec-
essarily but also because such variations may be having a
profound adverse effect on outcomes of some groups of patients.
Perhaps we need to concentrate less on acute neuroprotection
and more on controlling other aspects of care. Third, because
even larger trials of acute stroke are required, we need to find
ways to limit the paperwork and costs involved so that we can
afford to involve more centers, include more patients, and recruit
more quickly to trials. Fourth, we might need outcome measures
in phase II studies in humans that more resemble the models
used in animals, eg, 30-day fluid-attenuated inversion recovery/
baseline diffusion-weighted imaging ratio in magnetic resonance
imaging. Finally, we should consider whether our selection
criteria for trials are allowing the inclusion of patients whose
outcomes are not amenable to treatment. Penumbral imaging is
being studied elsewhere and offers 1 potential tool. With large
patient numbers in the SAINT trials and an onset-to-treatment
time of 4 hours, we consider that selection by penumbral
imaging would not have concentrated our sample by 30% to
40% and that we should therefore not have diluted a useful
treatment effect to undetectable levels.
Most of the preclinical data on NXY-059, as with other
neuroprotective drugs evaluated to date, assessed histologic
rather than behavioral outcome. The decision to move from
phase II to phase III in the NXY-059 program, however, was
based on long-term behavioral outcomes in marmosets.32 Al-
though it is unlikely that this explains the entire discrepancy
between preclinical animal studies and the results of clinical
trials in stroke patients, it does suggest that we should make the
outcome measures in preclinical and clinical trials more congru-
ent. For instance, perhaps we might be able to detect a biologic
effect of a drug in humans with more sensitivity by using
reduction in infarct size as an outcome measure in phase II
studies.33 The diffusion-weighted imaging/perfusion-weighted
imaging concept was not developed enough at the time when
phase II of NXY was being conducted. In addition, at that time
very few centers in the world had the ability to perform stroke
magnetic resonance imaging in the acute setting.
In summary, the clinical program for NXY-059 has reached
its conclusion: the treatment had a good safety profile but was
ineffective, and we claim no glimmers of hope among subgroups.
The field of neuroprotection has suffered a major setback from
which it can only recover through rigorous examination of all
aspects of the development process. In the meantime, stroke care
can still be improved through early restoration of perfusion
and consistent application of high standards of care through-
out the period of hospitalization and beyond.
Appendix
Steering Committee: K.R. Lees, Glasgow, Scotland (chair; principal
investigator of SAINT I); A. Shuaib (principal investigator of
SAINT II), Edmonton, Canada; T. Ashwood, So¨derta¨lje, Sweden
(sponsor representative); A. Davalos, Barcelona, Spain; S. Davis,
Melbourne, Australia; H.C. Diener, Essen, Germany; J. Grotta,
Houston, Tex; P. Lyden, San Diego, Calif; W. Wasiewski, Wilming-
ton, Del (sponsor representative).
Table 3. Baseline Parameters That Were Identified as
Significant Predictors of Outcome (Final mRS, Noncategorized)
at 90 Days Based on a Stepwise Search
Baseline Factor OR Estimate 95% CI P Value
Baseline NIHSS total 0.814 0.80–0.83 0.0001
Age in years at date of consent 0.964 0.96–0.97 0.0001
Neutrophils at baseline* 0.944 0.92–0.96 0.0001
Baseline glucose value, mmol/L 0.934 0.91–0.95 0.0001
Time from stroke onset to study
drug, min
0.997 1.00–1.00 0.0001
Side of infarction, left 1.277 1.13–1.44 0.0001
ORs are based on proportional odds across the full mRS. An OR1 indicates
a decrease in the predicted odds of a favorable outcome.
*Continuous variable with 109 as the unit.
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Data and Safety Monitoring Board: S. Pocock, London, England
(chair); H. Adams, Iowa City, Iowa; P. Bath, Nottingham, England;
D. Oakes, Rochester, NY; N.G. Wahlgren, Stockholm, Sweden; T.
Collier (Data and Safety Monitoring Board statistician).
Study Team Statisticians: V. Alderfer, Wilmington, Del; U.
Emeribe, Wilmington, Del; A. Stoltenberg, So¨derta¨lje, Sweden.
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